A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This single arm study will evaluate the safety and tolerability of ribavirin in combination
with PEGASYS in patients with chronic hepatitis C. Patients will receive ribavirin 800mg, or
1000-1200mg po daily, according to HCV genotype and body weight (< and >75kg)in combination
with PEGASYS 180micrograms sc weekly. The anticipated time on study treatment is 3-12 months,
and the target sample size is >500 individuals.